Citius Oncology, Inc. CTOR Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost at other companies
Other financials
Where this comes from
Reported directly by Citius Oncology, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost.
The official record: Citius Oncology, Inc.’s 10-K, filed December 23, 2025, on SEC EDGAR. View the filing →
Ask your AI about Citius Oncology, Inc.'s deferred tax assets, tax deferred expense, compensation and benefits, share-based compensation cost.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Citius Oncology, Inc.'s deferred tax assets, tax deferred expense, compensation and benefits, share-based compensation cost?
- Citius Oncology, Inc. (CTOR) reported deferred tax assets, tax deferred expense, compensation and benefits, share-based compensation cost of $1.93M in Q3 2025.